We evaluated the prognostic factors associated with survival and disease control rate using the variables of age ≥ 65 years, sex, etiology of HCC, ALBI score, vascular invasion, BCLC stage, largest tumor size ≥5 cm, macrovascular invasion, extrahepatic metastasis, AFP ≥ 400 ng/ml, concurrent treatment with regorafenib, and TTP with sorafenib > median (5.5 months) (Table S2–S5). This evidence concerns the gene AFP and neoplasm.